Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24514518 | 0.92 | HRH3 (0.49) | SIGMAR1HRH3BCHEHTR6SLC6A2 | |
| SCHEMBL25108479 | 0.90 | HRH3 (0.41) | SIGMAR1HRH3BCHEHTR6SLC6A2 | |
| SCHEMBL25108480 | 0.87 | SIGMAR1 (0.47) | SIGMAR1HRH3BCHEHTR6CHKA | |
| SCHEMBL24514225 | 0.82 | HRH3 (0.47) | SIGMAR1HRH3BCHEHTR6SLC6A2 | |
| SCHEMBL25110451 | 0.79 | CHKA (0.47) | SIGMAR1HRH3RORCCHKAKDM4E | |
| SCHEMBL25110235 | 0.77 | RORC (0.45) | SIGMAR1HRH3RORCCHKAKDM4E | |
| SCHEMBL25481265 | 0.77 | RORC (0.42) | SIGMAR1HRH3RORCCHKAKDM4E | |
| SCHEMBL25109489 | 0.76 | RORC (0.44) | SIGMAR1HRH3RORCCHKAKDM4E | |
| SCHEMBL22794339 | 0.76 | RORC (0.44) | RORCHTR6CHKA | |
| SCHEMBL25111066 | 0.74 | CHKA (0.46) | RORCCHKASLC6A2SLC6A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | SIGMAR1 2336/4885HRH3 1490/4885RORC 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.